Title:
置換アリールアミド
Document Type and Number:
Japanese Patent JP2005527586
Kind Code:
A
Abstract:
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
Inventors:
William Kay, Hugman
Lin, Linus S
Shere, Siurenik Kay
Lin, Linus S
Shere, Siurenik Kay
Application Number:
JP2003583993A
Publication Date:
September 15, 2005
Filing Date:
April 01, 2003
Export Citation:
Assignee:
MERCK & COMPANY INCOPORATED
International Classes:
A61K31/166; A61K31/343; A61K31/381; A61K31/40; A61K31/402; A61K31/403; A61K31/41; A61K31/415; A61K31/416; A61K31/4166; A61K31/4184; A61K31/42; A61K31/423; A61K31/4245; A61K31/426; A61K31/428; A61K31/437; A61K31/4375; A61K31/44; A61K31/4402; A61K31/4409; A61K31/4439; A61K31/4453; A61K31/455; A61K31/47; A61K31/4965; A61K31/505; A61K31/517; A61K31/519; A61P1/00; A61P1/10; A61P1/16; A61P3/04; A61P9/00; A61P11/06; A61P25/00; A61P25/02; A61P25/06; A61P25/08; A61P25/16; A61P25/18; A61P25/22; A61P25/28; A61P25/30; A61P43/00; C07C233/66; C07C235/42; C07C235/84; C07C237/20; C07C237/30; C07D207/27; C07D207/325; C07D207/327; C07D209/88; C07D213/40; C07D213/61; C07D213/81; C07D213/82; C07D215/48; C07D215/50; C07D217/02; C07D217/08; C07D217/26; C07D231/12; C07D231/14; C07D231/56; C07D233/32; C07D233/34; C07D233/90; C07D235/24; C07D239/28; C07D239/80; C07D241/24; C07D257/04; C07D261/18; C07D263/58; C07D295/14; C07D271/08; C07D277/20; C07D277/56; C07D277/68; C07D295/155; C07D307/85; C07D401/04; C07D471/04; C07D487/04; C07D495/04; C07D521/00; C07B61/00; C07D207/26; C07D207/32; (IPC1-7): C07C233/66; A61K31/166; A61K31/343; A61K31/381; A61K31/40; A61K31/402; A61K31/403; A61K31/41; A61K31/415; A61K31/416; A61K31/4166; A61K31/4184; A61K31/42; A61K31/423; A61K31/4245; A61K31/426; A61K31/428; A61K31/437; A61K31/4375; A61K31/44; A61K31/4402; A61K31/4409; A61K31/4439; A61K31/4453; A61K31/455; A61K31/47; A61K31/4965; A61K31/505; A61K31/517; A61K31/519; A61P1/00; A61P1/10; A61P1/16; A61P3/04; A61P9/00; A61P11/06; A61P25/00; A61P25/02; A61P25/06; A61P25/08; A61P25/16; A61P25/18; A61P25/22; A61P25/28; A61P25/30; A61P43/00; C07C235/42; C07C235/84; C07C237/30; C07D207/27; C07D207/327; C07D209/88; C07D213/81; C07D213/82; C07D215/50; C07D217/08; C07D217/26; C07D231/12; C07D231/14; C07D231/56; C07D233/34; C07D233/90; C07D235/24; C07D239/28; C07D239/80; C07D241/24; C07D257/04; C07D261/18; C07D263/58; C07D271/08; C07D277/20; C07D277/56; C07D277/68; C07D295/14; C07D307/85; C07D401/04; C07D471/04; C07D487/04; C07D495/04
Attorney, Agent or Firm:
Yoshio Kawaguchi
Akio Ichiiri
Makoto Ono
Katsuma Osaki
Mitsuaki Tsubokura
Akio Ichiiri
Makoto Ono
Katsuma Osaki
Mitsuaki Tsubokura